<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973166</url>
  </required_header>
  <id_info>
    <org_study_id>C-13-TPS04</org_study_id>
    <nct_id>NCT01973166</nct_id>
  </id_info>
  <brief_title>Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo Removal</brief_title>
  <official_title>Randomized, Split-tattoo Study Comparing Safety and Efficacy of Picosecond and Nanosecond Q-switched Nd:YAG Lasers for Tattoo Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the investigational medical grade laser device to a
      marketed medical grade laser device for effectiveness in lightening or clearing unwanted
      tattoos. This study will also compare any side effects from treatment with the devices.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tattoo clearing at 12 weeks post-final laser treatment for each treatment arm as assessed by blinded reviewers.</measure>
    <time_frame>12-weeks post-final laser treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tattoo clearing at 6 weeks post-final laser treatment for each treatment arm as assessed by blinded reviewers.</measure>
    <time_frame>6-weeks post-final treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tattoo clearing at 12 weeks post-final laser treatment for each treatment arm as assessed by the treating investigator.</measure>
    <time_frame>12-weeks post-final treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tattoo clearing at 12 weeks post-final treatment for each treatment arm as assessed by the subject</measure>
    <time_frame>12-weeks post-final treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject discomfort during laser treatment for each treatment arm.</measure>
    <time_frame>at time of Laser treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction for each treatment arm at 12 weeks post-final laser treatment.</measure>
    <time_frame>12-weeks post-final laser treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse device effects for each treatment arm during the study period.</measure>
    <time_frame>12-weeks post-final laser treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Tattoo Removal</condition>
  <arm_group>
    <arm_group_label>Picosecond Q-switched Laser Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nanosecond Q-switched Laser Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picosecond Q-switched Laser Treatment</intervention_name>
    <arm_group_label>Picosecond Q-switched Laser Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nanosecond Q-switched Laser Treatment</intervention_name>
    <arm_group_label>Nanosecond Q-switched Laser Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females or Males, 18 to 65 years of age (inclusive)

          -  Fitzpatrick Skin Type I - IV (Appendix 3)

          -  Tattoos containing black/blue ink alone or in combination with other colors

          -  Target tattoos older than 1 year

          -  Presence of tattoos equal or greater than 2 square inches, not to exceed 12 square
             inches

          -  Must be able to read, understand and sign the Informed Consent Form

          -  Must be willing and able to adhere to the treatment and follow-up schedule and
             post-treatment care instructions

          -  Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun
             exposure and use an approved sunscreen of SPF 50 or higher on the treated area
             starting 2 to 4 weeks before the treatment and/or every day for the duration of the
             study, including the follow-up period

          -  Willing to use hydroquinone approximately 4 weeks pre-treatment and post- treatment if
             required

          -  Willingness to have digital photographs taken of the treated area

          -  Agree not to undergo any other procedure(s) for the tattoo removal during the study

          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of
             birth control at least 3 months prior to enrollment and during the entire course of
             the study

        Exclusion Criteria:

          -  Participation in a study of another device or drug within 6 months prior to enrollment
             or during the study

          -  Prior treatment for tattoo removal in the target area, e.g., with q-switched laser,
             IPL, dermabrasion, electrocautery, cryotherapy

          -  History of allergic reaction to pigments following tattooing

          -  Presence of double tattoo in the treatment area

          -  History of allergy to local anesthetics

          -  History of allergy to topical antibiotics

          -  History of malignant tumors in the target area

          -  Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles

          -  Pregnant and/or breastfeeding

          -  Having an infection, dermatitis or a rash in the treatment area

          -  Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,
             e.g., uncontrolled hypertension

          -  Suffering from coagulation disorders or taking prescription anticoagulation
             medications

          -  History of keloid scarring, hypertrophic scarring or of abnormal wound healing

          -  History of immunosuppression/immune deficiency disorders or currently using
             immunosuppressive medications

          -  History of vitiligo, eczema, or psoriasis

          -  History of connective tissue disease, such as systemic lupus erythematosus or
             scleroderma

          -  History of seizure disorders due to light

          -  Any use of medication that is known to increase sensitivity to light, such as
             tetracycline

          -  History of herpes simplex and/or herpes zoster (shingles)

          -  History of radiation to the treatment area or undergoing systemic chemotherapy for the
             treatment of cancer

          -  History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation

          -  Systemic use of corticosteroid within 12 months of study participation

          -  Use of oral isotretinoin within 12 months of study participation and topical use of
             isotretinoin within 6 months on the treated area

          -  Anytime in life, having have used gold therapy (gold salts) for disorders such as
             rheumatologic disease or lupus

          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study

          -  Current smoker or history of smoking within 6 months of study participation

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tattoo Removal</keyword>
  <keyword>Q-switched laser</keyword>
  <keyword>Nd:YAG laser</keyword>
  <keyword>Nanosecond laser</keyword>
  <keyword>Picosecond laser</keyword>
  <keyword>Laser therapy</keyword>
  <keyword>Tattoo</keyword>
  <keyword>pulsed-laser</keyword>
  <keyword>laser treatment</keyword>
  <keyword>remove tattoo</keyword>
  <keyword>tattoo clearing</keyword>
  <keyword>tattoo lightening</keyword>
  <keyword>tattoo lighten</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

